There have been numerous recent advances in the management of glaucoma, not least the
development of new drugs to help manage raised intraocular pressure. In addition, the …

Introduction: Glaucoma affects a large number of people, and therapies for its management
are based on the use of adrenergic agonist/antagonists, carbonic anhydrase (CA) inhibitors …

Primary open angle glaucoma (POAG) is the most common type of glaucoma, and is
responsible for approximately 90% of glaucoma cases in North America. POAG is …

Our concepts of the glaucomas evolve as our understanding of disease processes
increases, technology advances, and our treatment strategies become more sophisticated …

Topical glaucoma medications have favorable safety and efficacy, but their use is limited by
factors such as side effects, nonadherence, costs, ocular surface disease, intraocular …

Glaucoma is a major cause of vision loss throughout the world. Treatment for glaucoma
consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent …

The majority of hypotensive antiglaucoma drugs, designed for intraocular pressure (IOP)
decrease, contain a preservative. A lifelong use of eyedrops provides the conditions for its …

The eyes are the window of the brain; various pathologies of the eyes can be explained on
the basis of neurological disorders and vice versa. Today, our only approach for the …

Glaucoma is a family of diseases commonly characterised by progressive optic neuropathy
with associated visual field deficits for which elevated intraocular pressure (IOP) is one of the …

The safety profile of the different glaucoma medications is an important issue when initiating
therapy in glaucomatous patients. The decision on which medication to prescribe depends …